Cargando…
Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial
BACKGROUND: Wound management is a critical factor when treating patients with the inherited skin fragility disease dystrophic epidermolysis bullosa (DEB). Due to genetic defects in structural proteins, skin and mucous epithelia are prone to blistering and chronic wounding upon minor trauma. Furtherm...
Autores principales: | Guttmann-Gruber, Christina, Piñón Hofbauer, Josefina, Tockner, Birgit, Reichl, Victoria, Klausegger, Alfred, Hofbauer, Peter, Wolkersdorfer, Martin, Tham, Khek-Chian, Lim, Seong Soo, Common, John E., Diem, Anja, Ude-Schoder, Katharina, Hitzl, Wolfgang, Lagler, Florian, Reichelt, Julia, Bauer, Johann W., Lang, Roland, Laimer, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576995/ https://www.ncbi.nlm.nih.gov/pubmed/34749770 http://dx.doi.org/10.1186/s13023-021-02062-2 |
Ejemplares similares
-
Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes
por: Guttmann-Gruber, Christina, et al.
Publicado: (2018) -
Profiling trial burden and patients’ attitudes to improve clinical research in epidermolysis bullosa
por: Prodinger, Christine, et al.
Publicado: (2020) -
Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study
por: Wally, Verena, et al.
Publicado: (2013) -
Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa
por: Welponer, Tobias, et al.
Publicado: (2021) -
Dystrophic Epidermolysis Bullosa
por: Yadav, Randhir Sagar, et al.
Publicado: (2018)